{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:33:43Z","timestamp":1787592823756,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T00:00:00Z","timestamp":1142899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1038\/sj.ijo.0803323","type":"journal-article","created":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T13:22:09Z","timestamp":1142947329000},"page":"1645-1652","source":"Crossref","is-referenced-by-count":23,"title":["Safety profile of orlistat: results of a prescription-event monitoring study"],"prefix":"10.1038","volume":"30","author":[{"given":"N V","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L V","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A W","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,3,21]]},"reference":[{"key":"BF0803323_CR1","first-page":"241","volume":"17","author":"ML Drent","year":"1993","unstructured":"Drent ML, van der Veen EA . Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: 241\u2013244.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0803323_CR2","unstructured":"Royal College of Physicians Working Party. Overweight and Obese Patients: Principles of Management with Particular Reference to the Use of Drugs. The Royal College of Physicians: London, 1997."},{"key":"BF0803323_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(05)63217-5","volume":"349","author":"J Fricker","year":"1997","unstructured":"Fricker J . Balancing the risks of anti-obesity pills. Lancet 1997; 349: 1374.","journal-title":"Lancet"},{"key":"BF0803323_CR4","unstructured":"Roche Products Limited. Orlistat, Summary of Product Characteristics. August 1998."},{"key":"BF0803323_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","volume":"21","author":"P Hollander","year":"1998","unstructured":"Hollander P, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study. Diabet Care 1998; 21: 1288\u20131294.","journal-title":"Diabet Care"},{"key":"BF0803323_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167\u2013172.","journal-title":"Lancet"},{"key":"BF0803323_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/0470853093.ch26","volume-title":"Pharmacovigilance","author":"SA Shakir","year":"2002","unstructured":"Shakir SA . PEM in the UK. In: Mann RD, Andrews E (eds). Pharmacovigilance. John Wiley & Sons Ltd: Chichester, UK, 2002, pp 333\u2013344."},{"key":"BF0803323_CR8","first-page":"17","volume-title":"Detection of New Adverse Drug Reactions","author":"MDB Stephens","year":"1992","unstructured":"Stephens MDB (ed) Introduction. In: Detection of New Adverse Drug Reactions, 3rd edn, Macmillan Publishers Ltd: Great Britain, 1992, p 17."},{"key":"BF0803323_CR9","first-page":"29","volume-title":"Pharmacoepidemiology","author":"BL Strom","year":"1994","unstructured":"Strom BL (ed) Sample size considerations for pharmacoepidemiology studies. In: Pharmacoepidemiology, 2nd edn, John Wiley & Sons Ltd: UK, 1994; 29\u201338."},{"key":"BF0803323_CR10","first-page":"143","volume-title":"Sample Size Tables for Clinical Studies","author":"D Machin","year":"1997","unstructured":"Machin D, Campbell MJ, Fayers PM, Pinol APY . Sample Size Tables for Clinical Studies, Table 7.1, Blackwell Science Ltd: Oxford, UK, 1997, pp 143\u2013150."},{"key":"BF0803323_CR11","first-page":"143","volume-title":"Sample Sizes for Clinical Studies","author":"D Machin","year":"1997","unstructured":"Machin D, Campbell MJ, Fayers PM, Pinol APY . Sample Sizes for Clinical Studies, Table 7.2, Blackwell Science Ltd: Oxford, UK, 1997, pp 143\u2013153."},{"key":"BF0803323_CR12","unstructured":"International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS\/WHO: Geneva, 1993."},{"key":"BF0803323_CR13","unstructured":"Guidelines on the Practice of Ethical Committees in Medical Research involving Human Subjects. Royal College of Physicians of London. August 1996."},{"key":"BF0803323_CR14","unstructured":"Multi-Centre Research Ethics Committees Guidance Notes. October, 19 (Appendix C). 2000. Ref Type: Generic [\n                    http:\/\/www.corec.org.uk\/wordDocs\/guideNotes.doc\n                    \n                   \u2013 page 19 Appendix C]."},{"key":"BF0803323_CR15","unstructured":"General Medical Council. General Medical Council booklet Confidentiality: Protecting and Providing Information; Frequently Asked Questions Q7, p9, 2004.."},{"key":"BF0803323_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","volume":"317","author":"RM Martin","year":"1998","unstructured":"Martin RM, Kapoor KV, Wilton LV, Mann RD . Underreporting of suspected adverse drug reactions to newly marketed (\u2018black triangle\u2019) drugs in general practice: observational study. BMJ 1998; 317: 119\u2013120.","journal-title":"BMJ"},{"key":"BF0803323_CR17","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"E Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA . Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872\u20131873.","journal-title":"Lancet"},{"key":"BF0803323_CR18","unstructured":"Roche Products Ltd. Orlistat \u2013 Summary of Product Characteristics 24 September 2004."},{"key":"BF0803323_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","volume":"69","author":"JO Hill","year":"1999","unstructured":"Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108\u20131116.","journal-title":"Am J Clin Nutr"},{"key":"BF0803323_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","volume":"20","author":"GA Bray","year":"1999","unstructured":"Bray GA, Greenway FL . Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805\u2013875.","journal-title":"Endocr Rev"},{"key":"BF0803323_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0033-0620(99)70008-3","volume":"42","author":"N Mikhail","year":"1999","unstructured":"Mikhail N, Golub MS, Tuck ML . Obesity and hypertension. Prog Cardiovasc Dis 1999; 42: 39\u201358.","journal-title":"Prog Cardiovasc Dis"},{"key":"BF0803323_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/bmj.321.7253.87","volume":"321","author":"M Persson","year":"2000","unstructured":"Persson M, Vitols S, Yue Q-Y . Orlistat associated with hypertension. BMJ 2000; 321: 87.","journal-title":"BMJ"},{"key":"BF0803323_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/bmj.322.7278.110","volume":"322","author":"MH Huber","year":"2001","unstructured":"Huber MH . Roche concludes that there is no evidence of a causal association (letter). BMJ 2001; 322: 110.","journal-title":"BMJ"},{"key":"BF0803323_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/bmj.322.7278.110","volume":"322","author":"M Persson","year":"2001","unstructured":"Persson M, Vitols S, Yue Q-Y . Author's reply (letter). BMJ 2001; 322: 110.","journal-title":"BMJ"},{"key":"BF0803323_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R, Li SK, Lau DC . Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27: 1437\u20131446.","journal-title":"Int J Obes Relat Metab Disord."},{"key":"BF0803323_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0149-2918(03)90009-9","volume":"25","author":"WY Leung","year":"2003","unstructured":"Leung WY, Neil Thomas G, Chan JC, Tomlinson B . Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58\u201380.","journal-title":"Clin Ther"},{"key":"BF0803323_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L . Xenical in the prevention of diabetes in obese subjects (Xendos) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabet Care 2004; 27: 155\u2013161.","journal-title":"Diabet Care"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/0803323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:38:11Z","timestamp":1684222691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/0803323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,21]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["BF0803323"],"URL":"https:\/\/doi.org\/10.1038\/sj.ijo.0803323","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,21]]}}}